Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2745710 | 0.97 | PKM (0.56) | PKMRAB9ATSHRHSD17B10FFAR3 | |
| SCHEMBL13738157 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL5614131 | 0.95 | PKM (0.54) | PKMRAB9ATSHRHSD17B10FFAR3 | |
| SCHEMBL5080859 | 0.94 | PKM (0.52) | PKMRAB9ATSHRHSD17B10FFAR3 | |
| SCHEMBL2746399 | 0.90 | PKM (0.50) | PKMRAB9ATSHRHSD17B10FFAR3 | |
| Hydrochloric Acid SCHEMBL2710449 | 0.88 | PKM (0.48) | PKMRAB9ATSHRHSD17B10FFAR3 | |
| SCHEMBL1733355 | 0.88 | PKM (0.48) | PKMRAB9ATSHRHSD17B10FFAR3 | |
| SCHEMBL12858182 | 0.88 | PKM (0.54) | PKMRAB9ATSHRHSD17B10FFAR3 | |
| Hydrochloric Acid SCHEMBL5000662 | 0.88 | PKM (0.48) | PKMRAB9ATSHRHSD17B10FFAR3 | |
| Hydrochloric Acid SCHEMBL4883393 | 0.86 | PKM (0.52) | PKMRAB9ATSHRHSD17B10FFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
| US-20250129033-A1 | METAP2 INHIBITORS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2025-04-24 | — | — | US | disclosed |
| EP-4479133-A1 | METAP2 INHIBITORS AND USES THEREOF | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. (IL) | 2024-12-25 | — | — | EP | disclosed |
| CN-118871428-A | METAP2 inhibitors and uses thereof | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 2024-10-29 | — | — | CN | disclosed |
| WO-2023156996-A1 | METAP2 INHIBITORS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-08-24 | — | — | WO | disclosed |
| US-9707757-B2 | Photosensitive negative resin composition | CANON KABUSHIKI KAISHA (JP) | 2017-07-18 | — | — | US | disclosed |
| US-9707757-B2 | Photosensitive negative resin composition | CANON KABUSHIKI KAISHA (JP) | 2017-07-18 | — | — | US | disclosed |
| EP-2771740-B1 | PHOTOSENSITIVE NEGATIVE RESIN COMPOSITION, FINE STRUCTURE, PRODUCTION PROCESS OF FINE STRUCTURE AND LIQUID EJECTION HEAD | CANON KK (JP) | 2017-03-15 | — | — | EP | disclosed |
| EP-2610248-B1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING A PALLADIUM COMPOUND | TEIJIN PHARMA LTD (JP) | 2016-06-08 | — | — | EP | disclosed |
| US-9268222-B2 | Photosensitive negative resin composition, fine structure, production process of fine structure and liquid ejection head | CANON KABUSHIKI KAISHA (JP) | 2016-02-23 | — | — | US | disclosed |
| EP-1474139-A4 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK & CO INC (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050070720-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
| EP-1474139-A2 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | Merck & Co., Inc. (US) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003065983-A2 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK & CO., INC. (US) | 2003-08-14 | — | — | WO | disclosed |
| US-20030130354-A1 | 1-(Adamantyl) amidines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission | VERNALIS RESEARCH LIMITED | 2003-07-10 | — | — | US | disclosed |
| US-6500866-B1 | PROPHYLAXIS OF NEURODEGENERATIVE DISORDERS BY ADMINISTERING N-METHYL-D-ASPARTATE RECEPTOR ANTAGONIST OR PRODRUGS SUCH AS 3,5-DIMETHYL-1-ADAMANTANECARBOXIMIDAMIDE HYDROCHLORIDE | VERNALIS RESEARCH LIMITED (GB) | 2002-12-31 | — | — | US | disclosed |
| EP-1037874-B1 | 1-(ADAMANTYL)AMIDINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RES LTD (GB) | 2002-10-09 | — | — | EP | disclosed |
| EP-1037874-A1 | 1-(ADAMANTYL)AMIDINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999031051-A1 | 1-(ADAMANTYL)AMIDINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | CEREBRUS PHARMACEUTICALS LIMITED (GB) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | PKM 1098/4885RAB9A 3422/4885TSHR 3850/4885 |
| US-20050070720-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | HSD11B1, HSD17B1, HSD11B2 | PKM 441/4885RAB9A 4415/4885TSHR 2731/4885 |
| US-20030130354-A1 | 1-(Adamantyl) amidines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission | SLC1A2, GRIN1, GRM1 | PKM 2833/4885RAB9A 774/4885TSHR 888/4885 |
| US-20250129033-A1 | METAP2 INHIBITORS AND USES THEREOF | METAP2, METAP1, SPINT2 | PKM 3243/4885RAB9A 1442/4885TSHR 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.